Handelsavisen
prelaunch
Companies Healthcare RHON.KL
RH
RHON.KL Bursa Malaysia Pharmaceuticals

Rhone Ma Holdings Bhd

$0,67
Open in Charts → Attach watcher ⌖
USD
Set alert
LatestRhone Ma Holdings projects 14% core earnings CAGR through FY28
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
3,65 %
Op margin
11,2 %
ROE
2,0 %
Net margin
6,2 %
Debt / equity
0,18
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Rhone Ma Holdings Bhd is a pharmaceutical company that develops, manufactures, and distributes prescription and over-the-counter drugs, primarily in Malaysia and Southeast Asia.

Business. Rhone Ma Holdings Bhd (RHON.KL) is a pharmaceutical company engaged in the development and sale of pharmaceutical products. The firm is headquartered in Malaysia and is primarily listed on the Bursa Malaysia stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
2,0 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

1
  • MARKETSRhone Ma Holdings projects 14% core earnings CAGR through FY282026-07-16
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to RHON.KL. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    Briefing · model-assisted

    Rhone Ma Holdings Berhad (RHON.KL) is currently undergoing its first formal analysis, meaning there is no prior historical basis for computing material changes or performance deltas. Consequently, no specific operational shifts, financial adjustments, or strategic pivots can be identified from the available data to drive a narrative of change. The company’s current profile indicates a lack of external market engagement metrics, with zero recorded officers, analysts, index memberships, or top holders in the dataset. This absence of tracked stakeholders suggests that the entity is either newly listed, thinly traded, or not yet integrated into standard financial monitoring frameworks. Cross-source signal analysis reveals minimal activity, with only a single dispatch recorded on July 16, 2026, amidst a broader period of zero daily dispatches from late June through mid-July 2026. The sentiment for this isolated event is undefined, and the overall volume of information flow remains negligible. Given the lack of material changes, watcher signals, or saga developments, the significance of Rhone Ma Holdings Berhad’s current status is defined by its informational vacuum. Investors and analysts lack the foundational data required to assess risk, valuation, or strategic direction, limiting any substantive financial commentary at this stage.

    Signals & dispatch

    peak dispatch · 2026-07-16

    Composite-score breakdown

    Synthesis

    Business

    Rhone Ma Holdings Bhd (RHON.KL) is a pharmaceutical company engaged in the development and sale of pharmaceutical products. The firm is headquartered in Malaysia and is primarily listed on the Bursa Malaysia stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    Rhone Ma Holdings Bhd maintains a conservative capital structure with a debt-to-equity ratio of 0.18, indicating a low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 4.75, suggesting strong short-term liquidity. However, the company's net cash position is negative after subtracting total debt, which could signal potential liquidity constraints in the near term.

    In terms of profitability, the company's return on equity (ROE) is 1.96%, and its return on assets (ROA) is 1.42%. These figures are below the industry median for ROE and ROA in the pharmaceutical sector, indicating that the company is underperforming relative to its peers in terms of capital efficiency and asset utilization.

    The company's revenue is primarily concentrated in Malaysia and Southeast Asia, with no disclosed breakdown of segment or geographic revenue. This lack of diversification could expose the company to regional economic and regulatory risks, particularly in a sector that is highly sensitive to healthcare policy changes.

    Looking ahead, the company's growth trajectory is expected to remain modest, with no significant revenue growth projected in the current or next fiscal year. Historical revenue trends show a stable but non-explosive growth pattern, which is consistent with the company's current market position and industry dynamics.

    The company's risk profile is moderate, with a low dilution risk and a medium liquidity risk. The risk assessment highlights a key flag: the company's net cash is negative after subtracting total debt, which could impact its ability to fund operations or invest in growth opportunities without external financing.

    Recent filings and transcripts do not indicate any major strategic shifts or significant events that would alter the company's current trajectory. The company appears to be maintaining a steady course, with no major new product launches or market expansions disclosed in the latest available documents.

    Rhone Ma Holdings Berhad (RHON.KL) is currently undergoing its first formal analysis, meaning there is no prior historical basis for computing material changes or performance deltas. Consequently, no specific operational shifts, financial adjustments, or strategic pivots can be identified from the available data to drive a narrative of change. The company’s current profile indicates a lack of external market engagement metrics, with zero recorded officers, analysts, index memberships, or top holders in the dataset. This absence of tracked stakeholders suggests that the entity is either newly listed, thinly traded, or not yet integrated into standard financial monitoring frameworks. Cross-source signal analysis reveals minimal activity, with only a single dispatch recorded on July 16, 2026, amidst a broader period of zero daily dispatches from late June through mid-July 2026. The sentiment for this isolated event is undefined, and the overall volume of information flow remains negligible. Given the lack of material changes, watcher signals, or saga developments, the significance of Rhone Ma Holdings Berhad’s current status is defined by its informational vacuum. Investors and analysts lack the foundational data required to assess risk, valuation, or strategic direction, limiting any substantive financial commentary at this stage.

    Key takeaways
    • Rhone Ma Holdings Bhd has a conservative capital structure with a low debt-to-equity ratio of 0.18.
    • The company's ROE and ROA are below the industry median, indicating underperformance in capital efficiency and asset utilization.
    • Revenue is concentrated in Malaysia and Southeast Asia, exposing the company to regional economic and regulatory risks.
    • The company's growth trajectory is expected to remain modest, with no significant revenue growth projected in the near term.
    • The company faces a medium liquidity risk due to a negative net cash position after subtracting total debt.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 4

    Revenue grew 32% year-over-year to MYR 223.7 million, demonstrating strong top-line expansion momentum.

    Free cash flow surged 536% to MYR 12.2 million, reflecting exceptional cash generation capabilities.

    Cash conversion ratio of 5.1 is best-in-class compared to the cohort median of 0.95.

    Long-term debt decreased to MYR 20.6 million, improving the balance sheet strength relative to prior periods.

    BEAR CASE · 4

    The company faces high credit risk, which could impair financial stability and increase borrowing costs.

    Medium liquidity risk suggests potential challenges in meeting short-term obligations or trading constraints.

    Net income growth of 25.7% lagged behind the 32% revenue growth, indicating margin compression pressures.

    Return on assets of 1.42% remains low, suggesting limited efficiency in generating profits from total assets.

    In focus — financials by report

    Annual
    ANNUALFiled 2025-02-19
    FY 2025 · Full-year highlights

    Revenue MYR 211.4M, +4,2% YoY; Operating income +2,8% YoY.

    RevenueMYR 211.4M+4,2 % YoY
    Operating incomeMYR 20.4M+2,8 % YoY
    Net incomeMYR 12.3M+1,9 % YoY
    Free cash flowMYR 9.9M−0,5 % YoY
    EPS
    Operating cash flowMYR 18.4M+131,4 % YoY
    Financials
    Income statement
    RevenueMYR 211.4M
    Gross profitMYR 59.5M
    Operating incomeMYR 20.4M
    Net incomeMYR 12.3M
    Margins
    Gross margin28.1%
    Operating margin9.7%
    Net margin5.8%
    FCF margin4.7%
    Balance sheet
    Total assetsMYR 225.2M
    Total liabilitiesMYR 57.4M
    Total equityMYR 167.8M
    Cash & equivalents
    Long-term debtMYR 23.9M
    Cash flow
    Operating cash flowMYR 18.4M
    CapEx-MYR 1.4M
    Free cash flowMYR 9.9M
    SBC
    P&L flow · revenue → net income
    Revenue MYR 51.8MOperating costs MYR 46.0MNet income MYR 3.2M
    Highlights
    • Revenue MYR 211.4M, +4,2% YoY
    • Operating income +2,8% YoY
    • Net income +1,9% YoY
    • Free cash flow −0,5% YoY
    • Net margin 5.8%

    Valuation FY

    Market price
    $0,67
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $164.2M
    Net cash
    -$29.5M
    Current ratio
    4.8
    Debt / equity
    0.2
    ROA
    1.4%
    ROE
    2.0%
    Cash conversion
    510.0%
    CapEx / revenue
    -0.6%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin11,2 %Above median
    Net Margin6,2 %Above median
    ROE2,0 %Below median
    Capex / Rev-0,6 %Above P75
    D/E0,18Below median
    Cash Conv5,10Best in class

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Rhone Ma Holdings Bhd Market data — financials · 2026-05-29

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    RHON.KLCanonical
    Bursa Malaysia · USD

    Intel & risk

    peak dispatch · 2026-07-16
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2025-02-19 15:17 UTCEARNINGSAnnual results — FY 2025 Revenue MYR 211.4M · Net MYR 12.3M
    2024-02-20 15:26 UTCEARNINGSAnnual results — FY 2024 Revenue MYR 202.9M · Net MYR 12.1M
    2023-02-21 15:39 UTCEARNINGSAnnual results — FY 2023 Revenue MYR 198.2M · Net MYR 12.7M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage